Nurix Therapeutics to Discuss Phase 1 NX-5948 Data at EHA2024

Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on targeted protein modulation drugs for cancer and inflammatory diseases, announced a significant event scheduled for June 16, 2024. The company plans to host a webcast and conference call at 9:00 a.m. ET (3:00 p.m. CEST) on that day, following their presentation at the European Hematology Association Congress (EHA2024) in Madrid, Spain.

The webcast and call will discuss findings from an ongoing Phase 1 clinical trial of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader designed to treat patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. This presentation, part of the EHA2024 oral sessions, will include updated data from heavily pretreated patients, including those with BTK inhibitor resistance mutations and central nervous system involvement.

Key details of the webcast and conference call are as follows:
- Date and Time: Sunday, June 16, 9:00 a.m. ET / 3:00 p.m. CEST
- Access: The live webcast can be accessed through the Events and Presentations page in the Investors section of Nurix's website. Pre-registration is required to participate in the live conference call. A replay will be available on the Nurix website for approximately 30 days post-event.

The oral presentation at EHA2024 will feature the latest results from the NX-5948 study. The presentation details are:
- Title: Latest results from an ongoing first-in-human Phase 1a/b study of NX-5948, a selective Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other B-cell malignancies.
- Session: s445 Novel therapies in relapsed and refractory CLL and hairy cell leukemia
- Session Date and Time: Sunday, June 16, 11:30 a.m. – 12:45 p.m. CEST
- Location: Hall Velasquez
- Presenter: Dr. Kim Linton
- Abstract #: S155

NX-5948 is an investigational, orally bioavailable, brain-penetrant small molecule degrader of BTK. It is currently under evaluation in a Phase 1 clinical trial involving patients with relapsed or refractory B cell malignancies. Previous studies have shown that NX-5948 is highly effective against a range of tumor cell lines resistant to current BTK inhibitor therapies, a crucial factor for heavily pretreated CLL/SLL patients. Additional information about the clinical trial can be found at clinicaltrials.gov (NCT05131022).

Nurix Therapeutics is headquartered in San Francisco, California. The company is dedicated to pioneering small molecule and antibody therapies through the modulation of cellular protein levels, targeting cancer, inflammatory conditions, and other severe diseases. The company leverages its expertise in E3 ligases and proprietary DNA-encoded libraries through its DELigase platform to identify and develop novel drug candidates. Nurix’s clinical-stage pipeline includes targeted protein degraders of BTK and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, which regulate immune cell types such as T cells and NK cells.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!